{"nctId":"NCT02579057","briefTitle":"Sub-Q Versus IV Furosemide in Acute Heart Failure","startDateStruct":{"date":"2016-02","type":"ACTUAL"},"conditions":["Congestive Heart Failure"],"count":40,"armGroups":[{"label":"Furosemide Injection Solution, USP","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Furosemide Injection Solution, USP"]},{"label":"Furosemide Injection Solution (SCP-101)","type":"EXPERIMENTAL","interventionNames":["Drug: Furosemide Injection Solution (SCP-101)"]}],"interventions":[{"name":"Furosemide Injection Solution (SCP-101)","otherNames":["sc Furosemide"]},{"name":"Furosemide Injection Solution, USP","otherNames":["IV furosemide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.\n* Male and female subjects \\> 18 years of age\n* History of at least 3 months treated heart failure (NYHA class II/III/IV), or recent hospitalization for heart failure; presenting to Heart Failure Bridge Clinic (HFBC) with decompensated heart failure symptoms including elevated jugular venous pressure, dyspnea and peripheral edema where the decision is made to give IV diuretics\n* Able to participate in the study in the opinion of the investigator\n* Has the ability to understand the requirements of the study and is willing to comply with all study procedures\n\nExclusion Criteria:\n\n* Presenting with symptoms where it is anticipated that there is a high chance of hospitalization such as ischemia, uncontrolled arrhythmia, infection, hemodynamic instability (elevated or low blood pressure), respiratory compromise, or electrolyte abnormalities (\\>25% increase in creatinine from baseline, potassium, hyponatremia).\n* On experimental medication or currently participating in a cardiovascular research study.\n* Presence or need for urinary catheterization, urinary tract abnormality or disorder interfering with urination\n* Any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study\n* Inability to comply with study requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Urine Output","description":"The volume of urine produced in milliliters over the 6 hours after drug delivery will be measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1636","spread":"875"},{"groupId":"OG001","value":"1515","spread":"1000"}]}]}]},{"type":"SECONDARY","title":"Heart Failure Symptom Scoring/Symptom Improvement","description":"Will evaluate if subjective heart failure symptoms improve over the period of diuresis. Measured by Kansas City Cardiomyopathy Questionnaire","classes":[]},{"type":"SECONDARY","title":"Number of Participants With Side Effects","description":"Cumulative total of pain, local skin reactions (including hematoma and induration) and electrolyte abnormalities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Urine Sodium","description":"Total urinary sodium produced during the 6 hour urine collection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"35.3"},{"groupId":"OG001","value":"32.8","spread":"43.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Hypokalemia"]}}}